Intercept Pharmaceuticals Inc (ICPT)

Add to Watchlists
Create an Alert
Quickflows
46.52 -1.39  -2.90% NASDAQ Jul 1, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All ICPT News

News

View All Events

Events

Date Type Description
08/07/2020 08:30 EDT Misc Intercept Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2020
08/07/2020 Earnings Intercept Pharmaceuticals Inc Second Quarter Earnings in 2020 Release
05/11/2020 08:30 EDT Misc Intercept Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
05/11/2020 Earnings Intercept Pharmaceuticals Inc First Quarter Earnings Result for 2020
02/25/2020 08:30 EST Misc Intercept Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
02/25/2020 Earnings Intercept Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
02/25/2020 Misc Intercept Pharmaceuticals Inc Annual Report for 2019
11/05/2019 08:30 EST Misc Intercept Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Intercept Pharmaceuticals Inc Third Quarter Earnings for 2019 Release
08/07/2019 08:30 EDT Misc Intercept Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 272.40M
Total Expenses (TTM) 584.33M
Net Income (TTM) -347.39M

Balance Sheet View Statement

Total Assets (Quarterly) 662.38M
Total Liabilities (Quarterly) 697.10M
Shareholders Equity (Quarterly) -34.72M

Cash Flow Statement View Statement

Cash from Operations (TTM) -251.92M
Cash from Investing (TTM) -211.64M
Cash from Financing (TTM) 456.61M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.interceptpharma.com
  • Investor Relations URL: http://ir.interceptpharma.com/index.cfm
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Aug. 07, 2020
  • Last Earnings Release: May. 11, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 46.52
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
CIG4924 CI Global Health Sciences Corp Cl Y 5.45%
F0000155EU ST Healthcare Innovations 9 F CA 2.97%
F000014EGP ST Healthcare Innovations 8 CA 2.89%
MCC214 Next Edge Bio-Tech Plus F 2.85%
F0000142NF FT Innovative Health Care CA 2.31%
SBIO ALPS Medical Breakthroughs ETF 1.83%
VLIIX Value Line Capital Appreciation Instl 1.48%
LABU Direxion Daily S&P Biotech Bull 3X ETF 0.85%
PSC Principal US Small Cap Mlt Fac Ind ETF 0.65%

Comparables

Edit
MDGL Madrigal Pharmaceuticals Inc
VKTX Viking Therapeutics Inc
BMY Bristol-Myers Squibb Co
GERN Geron Corp
GILD Gilead Sciences Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.